Fig. 2From: Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysisPatient survival data. A Progression-free survival (PFS) and B Overall survival (OS). Gray area demarcates 95% confidence intervals. All survival data are uncensoredBack to article page